Optimizing glucose regulation includes several pathways. It starts with limiting the absorption in the gut and then release of insulin from the pancreas, the sensitivity of insulin receptors on cells…
Standard pharmaceutical interventions for Alzheimer’s disease have thus far proven to be insufficient, with over 400 clinical trials to date being deemed unsuccessful and going unapproved1. Certain pharmaco-therapies like memantine or donanemab offered a delay in symptom progression but never offered any reversal of symptoms or treatment of pathology2.
In late July 2022 it was announced that Amazon would be acquiring primary health-care provider One Medical in an all-cash buyout for $18 a share, amounting to roughly $3.9 billion1. This marked their largest excursion into the healthcare sector to date. NBC quotes Neil Lindsay, a higher-up in Amazon Health Services as saying healthcare was “high on the list of experiences that need reinvention1.”
Digital Journal, a reporting startup examining the impact of science, technology, and digital culture on the global landscape, recently put together a forecast on Allogeneic Stem Cells and their market for use and development: “Allogeneic Stem Cells Market Emerging Trends, Impact of Covid-19, Development Status, Fact and Figures, SWOT Analysis, Forecast up to 20281.”
As standard market price-points’ changes are being passed off as inflation, many consumers are feeling the pinch on their bank accounts. In reality the truth is that there’s less inflation, it’s probably closer to what’s called “price gouging” as supply networks become over stressed due to supply-chain issues related to the COVID-19 pandemic1.